AnalystChoice.com Brings You the Best Complimentary Research Report on PPHM, OCLS, FISV, SNPS, FMCN and PETM
NEW DELHI, INDIA--(Marketwire - August 17, 2009) - Analyst Choice has combined some of the
best financial and technical minds worldwide to bring you an array of free
quality equity research and reporting. Today we have begun in-depth
reporting on our website evaluating the current market condition of
Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Oculus Innovative Sciences
Inc. (NASDAQ: OCLS), Fiserv Inc. (NASDAQ: FISV), Synopsys Inc. (NASDAQ: SNPS), Focus Media Holding Ltd. (NASDAQ: FMCN) and Petsmart Inc. (NASDAQ: PETM).
You can now access these reports with many others by signing up for free at
While the world economy undergoes enormous pressure and unprecedented
actions are been taken to avoid the worst and boost the shrinking global
economic growth, our analysts brings you a bird's eye view of how the big
players in the different key sectors and industries of the NASDAQ and NYSE,
are coping. Sign up now by visiting the following link and receive free
access to the CFA reports listed in this release.
Our research and reporting style takes you closer to the basics and allows
you to understand the company's lifecycle on a peer-to-peer and
company-to-industry level.
By opting to register for our free membership on
http://www.analystchoice.com/, you will have access to these reports &
opinions. You can expect to have a brief analysis on the different key
aspects of these companies, that is:
-- Corporate Analysis
-- Financial Reporting
-- Sector & Industry Scrutiny
-- Buy, Hold, Sell Opinion
-- Technical Summary
We offer you proper technical guidance on your investment strategies; you
simply have to contact us for general inquiries on info@analystchoice.com
or for support on contactus@analystchoice.com
AnalystChoice.com is an independent financial research portal and as such
has not received any compensation by any of the above mentioned companies.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.